人狂犬病疫苗(Novartis ): 一种免疫刺激剂药物,由Novartis Vaccines & Diagnostics, Inc. (Novartis Vaccines & Diagnostics, Inc.)公司最早进行研发,目前全球最高研发状态为批准上市,作用机制: 免疫刺激剂,治疗领域: 感染,其他疾病,在研适应症: 狂犬病,在研机构: Chi
Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division, resulting in an industry leading pipeline. Today Novartis holds an R&D and investor update in London which will provide ...
* With the 2015 Annual Report, values back to 2011 were restated, as a result of a series of transactions during 2015. ** During this year, eye care division Alcon was spun off and became an own company. Thus, Alcon's revenues are not included. *** Reduced revenue due to Sandoz ...
Search Report and Written Opinion issued in Singapore Application No. 11201702401R, completed Mar. 29, 2018. Shakhov et al., “SMUCKLER/TIM4 is a distinct member of TIM family expressed by stromal cells of secondary lymphoid tissues and associated with lymphotoxin signaling” Eur. J. Immunol...
We use a number of adjusted, non-IFRS, measures to report the performance of our business, as described on page 58 of GSK’s 2017 Annual Report, including Adjusted results, free cash flow and CER growth rates. Non-IFRS measures may be considered in addition ...